Is liraglutide safe and effective in the elderly obese patients?: A single center experience.

Oral A, Küçük C, Kayalar Y

Medicine1 Apr 2025Cited by 1 (Europe PMC)

PMID40258760PMCIDPMC12014040DOI10.1097/md.0000000000042155PepBankPUB-40258760

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

01HumanObservational studyEfficacy outcome
In adults aged at least 60 years with obesity prescribed liraglutide, body-weight loss was 5.96% at week 4 (P<.0001); no control group was reported.
In plain wordsIn older adults with obesity, liraglutide was linked to 5.96% weight loss at week 4 compared with initial weight.
Peptide
Liraglutide
Outcome
DecreaseBody weight loss at week 4
Study
n = 32
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 4 weeksAs given in this study (human).
Measurements
Body-weight loss
5.96%
week4
P-value
< 0.0001
all reported weight-loss time points
Source sentences
Summary
The body weight loss percentages were 5.96% at week 4, 10.06% at week 8, 13.85% at week 12, and 15.80% at week 24 (all P < .0001).
2 context sentences(design, population, supporting numbers)
Summary · context
This retrospective cohort study included patients aged ≥ 60 years with a body-mass index (BMI) ≥ 27 or greater and other comorbidities, as well as those with an initial BMI ≥ 30.
Summary · context
All patients referred from a private tertiary clinic were prescribed liraglutide for obesity treatment.
Report a problemFND-4025876001
02HumanObservational studyEfficacy outcome
In adults aged at least 60 years with obesity prescribed liraglutide, body-weight loss was 10.06% at week 8 (P<.0001); no control group was reported.
In plain wordsIn older adults with obesity, liraglutide was linked to 10.06% weight loss at week 8 compared with initial weight.
Peptide
Liraglutide
Outcome
DecreaseBody weight loss at week 8
Study
n = 32
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 8 weeksAs given in this study (human).
Measurements
Body-weight loss
10.06%
week8
P-value
< 0.0001
all reported weight-loss time points
Source sentences
Summary
The body weight loss percentages were 5.96% at week 4, 10.06% at week 8, 13.85% at week 12, and 15.80% at week 24 (all P < .0001).
2 context sentences(design, population, supporting numbers)
Summary · context
This retrospective cohort study included patients aged ≥ 60 years with a body-mass index (BMI) ≥ 27 or greater and other comorbidities, as well as those with an initial BMI ≥ 30.
Summary · context
All patients referred from a private tertiary clinic were prescribed liraglutide for obesity treatment.
Report a problemFND-4025876002
03HumanObservational studyEfficacy outcome
In adults aged at least 60 years with obesity prescribed liraglutide, body-weight loss was 13.85% at week 12 (P<.0001); no control group was reported.
In plain wordsIn older adults with obesity, liraglutide was linked to 13.85% weight loss at week 12 compared with initial weight.
Peptide
Liraglutide
Outcome
DecreaseBody weight loss at week 12
Study
n = 32
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 12 weeksAs given in this study (human).
Measurements
Body-weight loss
13.85%
week12
P-value
< 0.0001
all reported weight-loss time points
Source sentences
Summary
The body weight loss percentages were 5.96% at week 4, 10.06% at week 8, 13.85% at week 12, and 15.80% at week 24 (all P < .0001).
2 context sentences(design, population, supporting numbers)
Summary · context
This retrospective cohort study included patients aged ≥ 60 years with a body-mass index (BMI) ≥ 27 or greater and other comorbidities, as well as those with an initial BMI ≥ 30.
Summary · context
All patients referred from a private tertiary clinic were prescribed liraglutide for obesity treatment.
Report a problemFND-4025876003
04HumanObservational studyEfficacy outcome
In adults aged at least 60 years with obesity prescribed liraglutide, body-weight loss was 15.80% at week 24 (P<.0001); no control group was reported.
In plain wordsIn older adults with obesity, liraglutide was linked to 15.80% weight loss at week 24 compared with initial weight.
Peptide
Liraglutide
Outcome
DecreaseBody weight loss at week 24
Study
n = 32
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 24 weeksAs given in this study (human).
Measurements
Body-weight loss
15.8%
week24
P-value
< 0.0001
all reported weight-loss time points
Source sentences
Summary
The body weight loss percentages were 5.96% at week 4, 10.06% at week 8, 13.85% at week 12, and 15.80% at week 24 (all P < .0001).
2 context sentences(design, population, supporting numbers)
Summary · context
This retrospective cohort study included patients aged ≥ 60 years with a body-mass index (BMI) ≥ 27 or greater and other comorbidities, as well as those with an initial BMI ≥ 30.
Summary · context
All patients referred from a private tertiary clinic were prescribed liraglutide for obesity treatment.
Report a problemFND-4025876004
05HumanObservational studyEfficacy outcome
At week 24, the source reported 100% of older adults prescribed liraglutide had lost more than 5% of initial weight; the sentence prints the same proportion for both thresholds.
In plain wordsIn older adults with obesity receiving liraglutide, the reported proportion losing more than 5% of initial weight at week 24 was 100%.
Peptide
Liraglutide
Outcome
Not applicableParticipants losing more than 5% of initial weight at week 24
Study
n = 32
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 24 weeksAs given in this study (human).
Measurements
participants
100%
lost more than 5% of initial weight at week 24
Source sentences
Summary
At week 24, 100% of the patients lost more than 5% and 10% of their initial weight, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
This retrospective cohort study included patients aged ≥ 60 years with a body-mass index (BMI) ≥ 27 or greater and other comorbidities, as well as those with an initial BMI ≥ 30.
Summary · context
All patients referred from a private tertiary clinic were prescribed liraglutide for obesity treatment.
Report a problemFND-4025876005
06HumanObservational studyEfficacy outcome
At week 24, the source reported 100% of older adults prescribed liraglutide had lost more than 10% of initial weight; the sentence prints the same proportion for both thresholds.
In plain wordsIn older adults with obesity receiving liraglutide, the reported proportion losing more than 10% of initial weight at week 24 was 100%.
Peptide
Liraglutide
Outcome
Not applicableParticipants losing more than 10% of initial weight at week 24
Study
n = 32
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 24 weeksAs given in this study (human).
Measurements
participants
100%
lost more than 10% of initial weight at week 24
Source sentences
Summary
At week 24, 100% of the patients lost more than 5% and 10% of their initial weight, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
This retrospective cohort study included patients aged ≥ 60 years with a body-mass index (BMI) ≥ 27 or greater and other comorbidities, as well as those with an initial BMI ≥ 30.
Summary · context
All patients referred from a private tertiary clinic were prescribed liraglutide for obesity treatment.
Report a problemFND-4025876006
07HumanObservational studySafety outcome
In older adults with obesity prescribed liraglutide, nausea was the most common observed adverse effect; no comparative incidence or event count was reported.
In plain wordsIn older adults with obesity on liraglutide, nausea was the most common reported side effect; there was no control comparison.
Peptide
Liraglutide
Outcome
Not applicableNausea
Study
n = 32
Outcome group
Adverse events · Gastrointestinal
Studied dose
Dose not stated
Source sentences
Summary
Nausea was the most common adverse effect observed, with no reported instances of pancreatitis.
2 context sentences(design, population, supporting numbers)
Summary · context
This retrospective cohort study included patients aged ≥ 60 years with a body-mass index (BMI) ≥ 27 or greater and other comorbidities, as well as those with an initial BMI ≥ 30.
Summary · context
All patients referred from a private tertiary clinic were prescribed liraglutide for obesity treatment.
Report a problemFND-4025876007
08HumanObservational studySafety outcome
In older adults with obesity prescribed liraglutide, no pancreatitis instances were reported; this is descriptive absence, not a statistically tested null or proof of safety.
In plain wordsIn older adults with obesity on liraglutide, no pancreatitis was reported; there was no control comparison.
Peptide
Liraglutide
Outcome
Not applicablePancreatitis
Study
n = 32
Outcome group
Adverse events · Gastrointestinal
Studied dose
Dose not stated
Source sentences
Summary
Nausea was the most common adverse effect observed, with no reported instances of pancreatitis.
2 context sentences(design, population, supporting numbers)
Summary · context
This retrospective cohort study included patients aged ≥ 60 years with a body-mass index (BMI) ≥ 27 or greater and other comorbidities, as well as those with an initial BMI ≥ 30.
Summary · context
All patients referred from a private tertiary clinic were prescribed liraglutide for obesity treatment.
Report a problemFND-4025876008

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 1
9 Oct 2026, 03:04 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.